Session Item

ESGO-ESTRO-ESP guidelines on cervical cancer were published in 2018. These guidelines were recently reviewed for an update which were presented at ESGO Conference 2022 and will be available soon. This presentation will provide updates on management guidelines including, adjuvant treatment after initial surgery and locally advanced cervical cancer (T1b3-T4a or LN positive). The updates include management of cervical cancer diagnosed on a simple hysterectomy (SH) specimen, adjuvant therapy after radical surgery and state-of-the-art non -surgical treatment for locally advanced cervical cancers. Principles of radiotherapy including EBRT, BT, concomitant chemotherapy and dose prescription etc. will be discussed.